Stock AnalizInnovAge Holding Corp. INNV
Medical/Nursing Services · IPO 2021 · data as of November 13, 2026
InnovAge Holding Corp. (INNV) is a healthcare company listed in the US with a market value of about $1.3B. In the twelve months to September 30, 2026 it had revenue of $1.0B and net income of $9M, a net margin of 0.9%.
Its overall Stock Analiz score is 2.2 out of 5 (weak). The strongest part is financial health (5/5); the weakest is value (1/5).
Key numbers: a P/E of 157.8, a price to free cash flow of 16.9, 5-year revenue growth of 9% a year, a 5-year average ROIC of -4%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 52% below the current price.
Score: 2.2 / 5
Checks passed
- P/FCF below 20
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Positive free cash flow
- Interest covered more than 5 times
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0B | $990M | $854M | $764M | $688M | $699M | $638M | $567M |
| Net income | $9M | -$3M | -$30M | -$21M | -$41M | -$7M | -$44M | $26M |
| Free cash flow | $76M | $50M | $27M | -$45M | -$3M | -$11M | -$25M | $32M |
| EPS (diluted) | $0.06 | $-0.02 | $-0.22 | $-0.16 | $-0.30 | $-0.05 | $-0.36 | $0.19 |
| Net margin | 0.9% | -0.3% | -3.5% | -2.8% | -5.9% | -0.9% | -6.9% | 4.6% |
| ROIC | — | 0.7% | -7.3% | -5.0% | -10.1% | -0.9% | -2.4% | 12.7% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $12.00, 27% above the current price; targets range from $10.00 to $14.00; the consensus rating is “Hold”; expected EPS is $0.45 for the fiscal year ending June 30, 2027.
Frequently asked questions
What is InnovAge Holding’s P/E ratio?
About 157.8, based on the last twelve months of diluted earnings per share (forward P/E about 20.1).
Is InnovAge Holding stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 52% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does InnovAge Holding pay a dividend?
Not currently.
Is InnovAge Holding a good stock to buy?
We do not give buy or sell advice. InnovAge Holding scores 2.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.